Beaumont Financial Advisors LLC Purchases 57 Shares of Stryker Co. (NYSE:SYK)

Beaumont Financial Advisors LLC boosted its position in shares of Stryker Co. (NYSE:SYK) by 2.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,150 shares of the medical technology company’s stock after acquiring an additional 57 shares during the quarter. Beaumont Financial Advisors LLC’s holdings in Stryker were worth $644,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in SYK. Keybank National Association OH lifted its position in shares of Stryker by 3.5% in the third quarter. Keybank National Association OH now owns 27,823 shares of the medical technology company’s stock valued at $7,603,000 after buying an additional 952 shares during the last quarter. Carnegie Capital Asset Management LLC grew its holdings in Stryker by 0.5% in the 4th quarter. Carnegie Capital Asset Management LLC now owns 96,241 shares of the medical technology company’s stock valued at $28,820,000 after buying an additional 497 shares in the last quarter. CoreCap Advisors LLC increased its position in Stryker by 3.9% during the 4th quarter. CoreCap Advisors LLC now owns 5,030 shares of the medical technology company’s stock worth $1,506,000 after buying an additional 191 shares during the period. DNB Asset Management AS lifted its holdings in shares of Stryker by 5.7% during the fourth quarter. DNB Asset Management AS now owns 76,413 shares of the medical technology company’s stock worth $22,883,000 after buying an additional 4,143 shares in the last quarter. Finally, LGT Capital Partners LTD. boosted its position in shares of Stryker by 24.4% in the fourth quarter. LGT Capital Partners LTD. now owns 434,997 shares of the medical technology company’s stock valued at $130,264,000 after acquiring an additional 85,240 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In related news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the transaction, the director now owns 14,242 shares in the company, valued at $4,856,522. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Stryker news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the transaction, the director now directly owns 14,242 shares of the company’s stock, valued at $4,856,522. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the transaction, the director now directly owns 3,755,128 shares in the company, valued at approximately $1,287,633,391.20. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock valued at $72,845,768 in the last ninety days. 5.90% of the stock is currently owned by insiders.

Stryker Stock Down 0.6 %

Shares of NYSE:SYK opened at $325.43 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $350.01 and its 200 day moving average is $312.50. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The stock has a market cap of $123.82 billion, a price-to-earnings ratio of 39.45, a PEG ratio of 2.64 and a beta of 0.89.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, beating the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter last year, the business posted $3.00 EPS. The company’s revenue for the quarter was up 11.8% on a year-over-year basis. On average, sell-side analysts forecast that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a $0.80 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a yield of 0.98%. Stryker’s dividend payout ratio (DPR) is presently 38.79%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on SYK. Royal Bank of Canada boosted their price objective on shares of Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Roth Mkm raised their price objective on Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Evercore ISI upped their price objective on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Finally, Wells Fargo & Company boosted their target price on shares of Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $340.45.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.